Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 30 | 2024Novo Initiates Ph1 Study for New Obesity Asset; Lemonaid GLP-1RA and Compounded Semaglutide Program; New Semaglutide HF Analysis Published; Alnylam’s Ph3 ATTR-CM Vutrisiran DataPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Other Aug 28 | 2024Dexcom Hosts Stelo Webinar; Libre 3 CGM Recall; Novartis Positive Ph3 Leqvio Trial Results; President Biden Releases Statement on AOM PricesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Aug 27 | 2024Lilly Launches Single-Dose Zepbound Vials; Omnipod 5 T2DM Approval; Novo Semaglutide Adolescent Obesity StudyPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Aug 27 | 2024FENIX Analysis: Pump/AID Promotional Materials Post-ADA 2024Purchase Blast
$599
Posted in: Glucose Monitoring, Other Aug 26 | 2024Dexcom launches Stelo OTC Glucose Biosensor in the USPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 23 | 2024Novo Ph1 GLP/GIP RA Obesity Study; Pfizer Ph1 Danuglipron Study; D&D Ph2b MASH Study; Skye Ph2 Nimacimab Obesity Trial Initiation; FDA Denies Intarcia’s T2DM DevicePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Aug 21 | 2024Lexicon Zynquista Adcom; Sesame to Offer Compounded SemaglutidePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Aug 20 | 2024Tirzepatide Three-Year Positive Pre-Diabetes and Weight-Loss Results; Medtronic CY Q2 ’24 (FY Q1 ’25) Earnings Update; Tandem iOS app update; August 19-22 CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Aug 15 | 2024Medicare Price Negotiations; Lilly Targets HCPs Promoting Compounded GLP-1RAs; Arrowhead to Advance Obesity Pipeline; New AZ Ph2 Oral GLP-1RA Obesity Trial; Rivus Ph2 HFpEF Topline Results; Zealand and Fractyl Q2 ’24 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Other Aug 15 | 2024FENIX Analysis: CGM Promotional Materials Post-ADA 2024Purchase Blast
$599
Posted in: Insulin Delivery, Other, SGLT2i Aug 13 | 2024Lilly Opens New R&D Center; Tandem t:connect iOS App Recall Update; Lexicon to Refocus Business Including Salesforce Layoffs; Novartis Loses Generic Entresto Case; Galectin Q2 ’24 EarningsPurchase Blast
$599
Posted in: Other Aug 12 | 2024Esperion and Skye Bioscience Q2 ’24 Earnings; Sernova Appoints New CEOPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Aug 12 | 2024Insulet, Senseonics, Arrowhead, Biocon, and Akero Q2 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Other Aug 08 | 2024Altimmune, Scholar Rock, Xeris, and Viatris Q2 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other Aug 08 | 2024Lilly Raises FY Guidance by $3B; Lilly Q2 ’24 Earnings; Novo Q2 ’24 London EventPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Aug 07 | 2024Abbott/Medtronic Strategic Partnership; Simplera Updates; Madrigal and MannKind Q2 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other Aug 07 | 2024STEP HFpEF Withdrawn; QM GLP/GIP Withdrawn; Novo Q2 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 07 | 2024Amgen, Terns, and 89bio Q2 ‘24 Earnings; NeuroBo Partners for QM Obesity Asset FormulationPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i Aug 06 | 2024Kerendia FINEARTS-HF Topline Results; Simplera CGM Approved by FDA; Novo Initiates Second Ph3 H2H Cagrisema vs. Tirzepatide T2DM Study; Ypsomed and MTD Complete BGM Business SalePurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Aug 02 | 2024Tandem, Lexicon, and Vertex Q2 ’24 Earnings; Novartis Sues FDA Over Entresto GenericPurchase Blast